340B MTM Savings Program

Unlocking Significant Savings Through Innovative Technology

Discover an innovative solution with the Aprexis 340B MTM Savings Program, utilizing our clinical triggering technology to identify and redirect traditionally ineligible prescriptions into 340B-qualified opportunities, generating substantial financial benefits for your entity.

How it Works

Innovative Technology

Our program identifies high cost prescriptions that are then funneled into interventions within our comprehensive and HRSA-compliant MTM program.

Enhanced Privacy MTM Program

Prioritizing confidentiality, this program guarantees that individuals with identified prescriptions experience a Comprehensive Medication Review (CMR) or a Targeted Medication Review (TMR) to manage chronic conditions, foster improved health outcomes, while reducing healthcare costs.

Clinical Touchpoints

During the clinical touchpoint, the pharmacist co-signs the prescription, making it eligible for 340B qualification. This process ensures compliance, while maximizing financial benefits.

Substantial Savings Potential

The pricing differential between 340B and non-340B for medications addressing complex disease states can lead to significant savings. Even with a modest volume of 340B-eligible prescription fills, the potential for substantial financial benefits remain.

Connect With Aprexis

To schedule a demo and learn more about how our medication therapy management services can help your organization improve patient medication adherence, health outcomes, and reduce the cost of care for populations please contact us.